Equities

BridgeBio Pharma Inc

BridgeBio Pharma Inc

Actions
  • Price (EUR)23.83
  • Today's Change0.000 / 0.00%
  • Shares traded35.00
  • 1 Year change-11.71%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments435472837
Total Receivables, Net------
Total Inventory------
Prepaid expenses242232
Other current assets, total185520
Total current assets478549889
Property, plant & equipment, net202546
Goodwill, net------
Intangibles, net262945
Long term investments------
Note receivable - long term------
Other long term assets201831
Total assets5466231,013
LIABILITIES
Accounts payable111212
Accrued expenses127102123
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0.30
Other current liabilities, total6.108.160
Total current liabilities144121135
Total long term debt1,7271,7081,705
Total debt1,7271,7081,705
Deferred income tax------
Minority interest129.694.84
Other liabilities, total183938
Total liabilities1,9011,8781,883
SHAREHOLDERS EQUITY
Common stock0.180.160.15
Additional paid-in capital1,481939842
Retained earnings (accumulated deficit)(2561)(1918)(1437)
Treasury stock - common(275)(275)(275)
Unrealized gain (loss)------
Other equity, total0.03(0.33)(0.13)
Total equity(1354)(1255)(870)
Total liabilities & shareholders' equity5466231,013
Total common shares outstanding175151147
Treasury shares - common primary issue6.196.196.19
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.